Rebecca Taub
Director Madrigal Pharmaceuticals
Dr. Rebecca Taub is a pioneering biopharmaceutical executive and Chief Executive Officer of Madrigal Pharmaceuticals, where she leads the development of groundbreaking therapies for metabolic and fibrotic liver diseases. Under her leadership, Madrigal achieved a historic milestone with the first-ever FDA approval of resmetirom (Rezdiffra™) for nonalcoholic steatohepatitis (NASH), revolutionizing treatment for this progressive liver condition.
A physician-scientist and serial entrepreneur, Dr. Taub co-founded Madrigal in 2011 and has since steered the company from discovery to commercialization, leveraging her deep expertise in hepatology, metabolic disorders, and translational medicine. Previously, she held key roles at VIA Pharmaceuticals and Merck Research Laboratories, where she advanced programs in cardiovascular and liver diseases.
Trained in medicine and molecular biology, Dr. Taub’s early academic work uncovered foundational mechanisms of liver regeneration and metabolic regulation. Her unique blend of clinical insight, scientific acumen, and executive leadership has positioned her as a transformative figure in addressing unmet needs in fibrotic diseases.
Seminars
- Understanding the development of Resmetirom based on serial liver biopsy testing to provide unambiguous histopathological evidence and rigorously assess fibrosis regression and MASH resolution to accelerate FDA approval
- Diagnosing and monitoring patients using non-invasive tests to stratify patients and monitor treatment response, to differentiate between cirrhotic from non-cirrhotic MASH, empowering clinicians to identify high-risk patients earlier and tailor therapies, boosting real-world adoption
